Speaking on the above topic is Dr Kevin Tan, Scientific Director & Assistant Professor, Biolynx Technologies & National University of Singapore, Singapore. He will be presenting at Drug Discovery World Asia 2012, part of a series of conferences at 5th Annual BioPharma Asia Convention 2012.
Dr Kevin Tan pursued his PhD at the Department of Microbiology NUS and his postdoctoral studies at the Laboratory of Molecular Parasitology, The Rockefeller University, New York, under the supervision of Professor George Cross. Upon his return to Singapore in 2003, he began his research on protozoan cell death focusing on PCD pathways in the enteric parasite Blastocystis and the malaria parasite Plasmodium falciparum. His research involves understanding the molecular mechanisms of protozoan PCD and translating that knowledge to accelerate drug discovery. Kevin is the founding Director of BioLynx Technologies, an NUS spin-out company focusing on the commercialization of fluorescent-tagged drugs for research and diagnosis.
Here are the topics that Dr Tan will be addressing:
Accelerating drug discovery with fluorescent-tagged antimalarials
1. New cell death mechanisms in malaria parasites revealed through fluorescent-tagged chloroquine
2. Differentiation between chloroquine sensitive and resistant strains
3. Rapid screening for co-drugs restoring chloroquine sensitivity in resistant parasites